MedTrace Logo

Intradialytic Kinetics of Cardiac Biomarkers During Hemodialysis and Hemodiafiltration

NCT06526702 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-10-07

No results posted yet for this study

Summary

This randomized, crossover study aims to investigate the intradialytic kinetics of selected cardiac biomarkers in patients with end-stage renal disease treated with dialysis. The cardiac biomarkers of interest include high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, brain natriuretic peptide, and a novel cardiac biomarker named secretoneurin.

In 24 patients treated with maintenance hemodialysis, the study will compare high-flux hemodialysis (HD) with post-dilution hemodiafiltration (HDF) to investigate:

* Baseline concentrations and week-to-week plasma variations of the cardiac biomarkers.
* Changes in the plasma concentrations of the cardiac biomarkers during high-flux HD and post-dilution HDF.
* Dialyzer clearance of the cardiac biomarkers in high-flux HD and post-dilution HDF.
* Adherence of the cardiac biomarkers to the dialyzer membrane.
* Concentrations of the cardiac biomarkers 30 minutes post-dialysis to investigate a potential rebound effect.

Additionally, a sub-study of 24 patients treated with peritoneal dialysis will investigate the baseline concentrations and week-to-week plasma variations of the same cardiac biomarkers.

Conditions

  • End Stage Renal Disease on Dialysis

Interventions

DEVICE

High-flux hemodialysis

FX CorDiax 100 dialyzer

DEVICE

Post-dilution hemodiafiltration

FX CorDiax 1000 dialyzer

Sponsors & Collaborators

  • Aalborg University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-12
Primary Completion
2025-04-10
Completion
2025-04-10

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06526702 on ClinicalTrials.gov